XM does not provide services to residents of the United States of America.
H
H

Hologic

Technical Summary

IndicatorValueTrend
IndicatorValueTrend
IndicatorValueTrend
IndicatorS3S2S1PR1R2R3

News

Hologic Inc Says On Sept 12, Board Authorized New Stock Repurchase Program, With Five-Year Term, To Repurchase Up To $1.5 Billion Of Common Stock

BRIEF-Hologic Inc Says On Sept 12, Board Authorized New Stock Repurchase Program, With Five-Year Term, To Repurchase Up To $1.5 Billion Of Common Stock Hologic Inc HOLX.O : HOLOGIC INC SAYS ON SEPT 12, BOARD AUTHORIZED NEW STOCK REPURCHASE PROGRAM, WITH FIVE-YEAR TERM, TO REPURCHASE UP TO $1.5 BILLION OF COMMON STOCK Source text for Eikon: [ID:n000
H

U.S. Constellation Energy, Eli Lilly, Talen Energy

U.S. RESEARCH ROUNDUP-Constellation Energy, Eli Lilly, Talen Energy Sept 13 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Constellation Energy, Eli Lilly and Talen Energy, on Friday. HIGHLIGHTS * Constellation Energy Corp CEG.O : Jefferies initiates with hold rating; target $183 * Eli Lilly LLY.N : JP Morgan raises target price to $1,100 from $1,050 * Moderna MRNA.O : JP Morgan cuts to underweight from neutral * Vo
A
C
C
F
F
H
H
H
I
K
W
F
D
T
Z
A
A
D
E
H
L

U.S. Hubspot, McDonald's, Tesla

U.S. RESEARCH ROUNDUP- Hubspot, McDonald's, Tesla July 30 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Hubspot, McDonald's and Tesla, on Tuesday. HIGHLIGHTS * Ameriprise Financial Inc AMP.N : KBW cuts target price to $460 from $470 * First Citizens Bancshares FCNCA.O : Jefferies raises target price to $2,460 from $2,005 * Hubspot Inc HUBS.N : TD Cowen cuts target price to $600 from $680 * McDonald's MCD.N : Piper
A
H
A
D
L
A
A
B

Hologic quarterly profit rises on strong demand for its women's health products

Hologic quarterly profit rises on strong demand for its women's health products July 29 (Reuters) - Medical technology company Hologic HOLX.O reported a higher third-quarter profit on Monday, driven by strong demand for its diagnostics and breast health products, but forecast revenue for the current quarter that fell short of Wall Street estimates.
H

Hologic Inc reports results for the quarter ended in June - Earnings Summary

Hologic Inc reports results for the quarter ended in June - Earnings Summary Hologic Inc HOLX.OQ reported quarterly adjusted earnings of $1.06​​ per share for the quarter ended in June, higher than the same quarter last year, when the company reported EPS of 93 cents. The mean expectation of sixteen analysts for the quarter was for earnings of $1.02 per share.
H

Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.